Projects & Grants
| Genetically modified donor T cells as a universal cell source for the immunotherapy of tumors using T lymphocytes equipped with a chimeric antigen receptor (CAR). | |
|---|---|
| Project Id | TRIO_FV40145 |
| Main solver | doc. RNDr. Michal Šimíček, PhD. |
| Period | 8/2019 - 12/2022 |
| Provider | Program TRIO |
| State | finished |
| Anotation | The aim of the project is to achieve the applicability of research and development results in advanced pharmaceuticals and biotechnology in the commercial, corporate sphere. The primary goal is to develop a T-cell cell line that will be not immunogenic (will not be destroyed by the recipient's immune system) and will not be immunotoxic (will not induce a non-specific immune response against recipient tissues). Such modified donor Tcells will be further genetically modified to express a specific, so called chimeric antigen receptor to ensure their specific antitumor response. It will be necessary to develop or specifically implement procedures and technologies for the mentioned cell modifications and cell production in a clinical scale. The final result is a highly specific and innovative cellular medicinal product that has a high therapeutic efficiency and a very high added value. Achieving this goal will require increased productivity and efficiency of research activities, both on the applicant's side and on the partner's, research organization, side. Effective cooperation between the commercial and the research organization will be stepped up. The implementation of the project will lead to the development of a new, entirely innovative product that will be highly attractive and flexible enough to be modified for different patient groups according to their type of cancer. Such a product can be used quickly and successfully in practice because there is a significant social as well as medical demand for it. |
